JHEP Reports

Papers
(The H4-Index of JHEP Reports is 38. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)
ArticleCitations
Copyright and information228
Increased carbohydrate deficient transferrin: Whisky or candy?145
Protective role of physical activity against HCC risk in type 2 diabetes: Evidence and public health perspectives90
Reply to: “Dynamic imaging of macrophages in MASLD: A major interest in insulin resistance and outside the liver”85
Copyright and information82
Predicting liver ablation volumes with real-time MRI thermometry81
Shunt magnitude is a key determinant of overt hepatic encephalopathy in patients undergoing TIPS78
Heterogeneity in intrahepatic macrophage populations and druggable target expression in patients with steatotic liver disease-related fibrosis77
Inevitability of disease recurrence after liver transplantation for NAFLD cirrhosis77
Erratum to “Opinion paper on the diagnosis and treatment of progressive familial intrahepatic cholestasis” [JHEP Reports 6 (2024) 100949]76
Induction of phospholipase A2 group 4C by HCV infection regulates lipid droplet formation73
Statistical precision of p values: A note on “Liver fibrosis progression analyzed with AI predicts renal decline”70
Comparative effectiveness of antidiabetic therapies on hepatic decompensation in patients with type 2 diabetes: A target trial emulation67
Identifying emergency presentations of chronic liver disease using routinely collected administrative hospital data59
Mapping the hemodynamic effects of terlipressin in patients with hepatorenal syndrome using advanced magnetic resonance imaging58
Editorial Board page58
Unaddressed concerns of potential follow up bias in the International PSC Registry57
Changing epidemiology of hepatocellular carcinoma in the Mediterranean area: A challenge for surveillance?54
Hepatitis C virus replication requires integrity of mitochondria-associated ER membranes54
AFP score and metroticket 2.0 perform similarly and could be used in a “within-ALL” clinical decision tool53
What to do about hepatocellular carcinoma: Recommendations for health authorities from the International Liver Cancer Association49
External validation of the IAIHG autoimmune hepatitis response criteria in a multicentric real-world cohort48
HCV microelimination in harm reduction centres has benefits beyond HCV cure but is hampered by high reinfection rates48
Time for a globally unified chronic HBV terminology?47
Development and validation of circulating protein signatures as diagnostic biomarkers for biliary tract cancer47
A small animal model of chronic hepatitis E infection using immunocompromised rats47
Epigenetics of alcohol-related liver diseases46
JMJD2D stabilises and cooperates with HBx protein to promote HBV transcription and replication46
Human umbilical cord mesenchymal stem cell-derived exosomes ameliorate liver steatosis by promoting fatty acid oxidation and reducing fatty acid synthesis45
MELD 3.i: A Bayesian framework for updating the model for end-stage liver disease score45
Liver stiffness measurement predicts clinical outcomes in autoimmune hepatitis45
Lower pretreatment HBV DNA levels are associated with better off-treatment outcomes after nucleo(s)tide analogue withdrawal in patients with HBeAg-negative chronic hepatitis B: A multicentre cohort st44
Intrahepatic T cell analysis reveals Th17 and MAIT17 enrichment in primary sclerosing cholangitis44
The weight of choices: Prioritizing lifestyle over GLP-1 receptor agonist therapy in managing MASLD43
Combined inhibition of bile salt synthesis and intestinal uptake reduces cholestatic liver damage and colonic bile salts in mice43
Editorial Board page42
Reply to: “Changing epidemiology of hepatocellular carcinoma in the Mediterranean area: A challenge for surveillance?”40
HBV001: Phase I study evaluating the safety and immunogenicity of the therapeutic vaccine ChAdOx1-HBV39
RAC1 as a novel therapeutic target for acute liver failure38
0.92839288711548